Literature DB >> 35686205

Preliminary Study of the Protectiveness of Vaccination Against the COVID-19 in the Outbreak of VOC Omicron BA.2 - Jilin City, Jilin Province, China, March 3-April 12, 2022.

Xuebin Fan1, Shan Lu2, Lu Bai1, Haican Liu2, Junshao Fu1, Xiaoxun Jin1, Yulong He3, Jinxing Lu2, Xiaoping Dong4,5,6,7.   

Abstract

What is already known about this topic?: An outbreak of coronavirus disease 2019 (COVID-19) of Omicron BA.2 emerged in Jilin City since March 3, 2022, which involved in 27,036 cases by April 12. The vaccination program with inactivated COVID-19 vaccines has been implemented since the beginning of 2021. What is added by this report?: The incidences of moderate, severe, and critical cases in the whole population of the group of 0+1 dose were 1.82-, 9.49-, and 3.85-fold higher than those in the group of 2 doses, and 5.03-, 44.47-, and ∞-fold higher than those received 3 doses vaccination. For the population ≥60 years, the incidences of moderate, severe, and critical cases in the group of 0+1 dose were 29.92, 9.62, and 4.27 per 100,000, showing 4.13-, 43.72-, and 4.85-fold higher than 2 doses, as well as 13.28-, 22.37-, and ∞-fold higher than 3 doses. What are the implications for public health practice?: The incidences of each type of COVID-19 in the population who were fully vaccinated or booster vaccinated in Jilin City were significantly lower than those who were unvaccinated and/or partially vaccinated. Booster vaccination with homologous inactivated vaccines induces stronger protectiveness for COVID-19 caused by variant of concern (VOC) Omicron. Copyright and License information: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2022.

Entities:  

Keywords:  Covid-19; Pneumonias; Protectiveness; Vaccinations

Year:  2022        PMID: 35686205      PMCID: PMC9167613          DOI: 10.46234/ccdcw2022.081

Source DB:  PubMed          Journal:  China CDC Wkly        ISSN: 2096-7071


  9 in total

1.  Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination.

Authors:  Rahul K Suryawanshi; Irene P Chen; Tongcui Ma; Abdullah M Syed; Noah Brazer; Prachi Saldhi; Camille R Simoneau; Alison Ciling; Mir M Khalid; Bharath Sreekumar; Pei-Yi Chen; G Renuka Kumar; Mauricio Montano; Ronne Gascon; Chia-Lin Tsou; Miguel A Garcia-Knight; Alicia Sotomayor-Gonzalez; Venice Servellita; Amelia Gliwa; Jenny Nguyen; Ines Silva; Bilal Milbes; Noah Kojima; Victoria Hess; Maria Shacreaw; Lauren Lopez; Matthew Brobeck; Fred Turner; Frank W Soveg; Ashley F George; Xiaohui Fang; Mazharul Maishan; Michael Matthay; Mary Kate Morris; Debra Wadford; Carl Hanson; Warner C Greene; Raul Andino; Lee Spraggon; Nadia R Roan; Charles Y Chiu; Jennifer A Doudna; Melanie Ott
Journal:  Nature       Date:  2022-05-18       Impact factor: 69.504

2.  SARS-CoV-2 Omicron Variant: Exploring Healthcare Workers' Awareness and Perception of Vaccine Effectiveness: A National Survey During the First Week of WHO Variant Alert.

Authors:  Mohamad-Hani Temsah; Fadi Aljamaan; Shuliweeh Alenezi; Khalid Alhasan; Abdulkarim Alrabiaah; Rasha Assiri; Rolan Bassrawi; Ali Alhaboob; Fatimah Alshahrani; Mohammed Alarabi; Ali Alaraj; Nasser S Alharbi; Rabih Halwani; Amr Jamal; Ayman Al-Eyadhy; Naif AbdulMajeed; Lina Alfarra; Wafa Almashdali; Amel Fayed; Fahad Alzamil; Mazin Barry; Ziad A Memish; Jaffar A Al-Tawfiq; Sarah Alsubaie
Journal:  Front Public Health       Date:  2022-03-25

3.  SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies.

Authors:  Sabrina Lusvarghi; Simon D Pollett; Sabari Nath Neerukonda; Wei Wang; Richard Wang; Russell Vassell; Nusrat J Epsi; Anthony C Fries; Brian K Agan; David A Lindholm; Christopher J Colombo; Rupal Mody; Evan C Ewers; Tahaniyat Lalani; Anuradha Ganesan; Emilie Goguet; Monique Hollis-Perry; Si'Ana A Coggins; Mark P Simons; Leah C Katzelnick; Gregory Wang; David R Tribble; Lisa Bentley; Ann E Eakin; Christopher C Broder; Karl J Erlandson; Eric D Laing; Timothy H Burgess; Edward Mitre; Carol D Weiss
Journal:  Sci Transl Med       Date:  2022-05-18       Impact factor: 17.956

4.  Protection against the Omicron Variant from Previous SARS-CoV-2 Infection.

Authors:  Heba N Altarawneh; Hiam Chemaitelly; Mohammad R Hasan; Houssein H Ayoub; Suelen Qassim; Sawsan AlMukdad; Peter Coyle; Hadi M Yassine; Hebah A Al-Khatib; Fatiha M Benslimane; Zaina Al-Kanaani; Einas Al-Kuwari; Andrew Jeremijenko; Anvar H Kaleeckal; Ali N Latif; Riyazuddin M Shaik; Hanan F Abdul-Rahim; Gheyath K Nasrallah; Mohamed G Al-Kuwari; Adeel A Butt; Hamad E Al-Romaihi; Mohamed H Al-Thani; Abdullatif Al-Khal; Roberto Bertollini; Patrick Tang; Laith J Abu-Raddad
Journal:  N Engl J Med       Date:  2022-02-09       Impact factor: 91.245

Review 5.  "Is Omicron mild"? Testing this narrative with the mutational landscape of its three lineages and response to existing vaccines and therapeutic antibodies.

Authors:  Vijay Rani Rajpal; Shashi Sharma; Avinash Kumar; Shweta Chand; Lata Joshi; Atika Chandra; Sadhna Babbar; Shailendra Goel; Soom Nath Raina; Behrouz Shiran
Journal:  J Med Virol       Date:  2022-04-27       Impact factor: 20.693

6.  Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19-Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection - United States, June 2021-February 2022.

Authors:  Ian D Plumb; Leora R Feldstein; Eric Barkley; Alexander B Posner; Howard S Bregman; Melissa Briggs Hagen; Jacqueline L Gerhart
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2022-04-15       Impact factor: 35.301

7.  Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel.

Authors:  Aharona Glatman-Freedman; Michal Bromberg; Yael Hershkovitz; Hanna Sefty; Zalman Kaufman; Rita Dichtiar; Lital Keinan-Boker
Journal:  Emerg Infect Dis       Date:  2022-04-01       Impact factor: 16.126

8.  Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.

Authors:  Ori Magen; Jacob G Waxman; Maya Makov-Assif; Roni Vered; Dror Dicker; Miguel A Hernán; Marc Lipsitch; Ben Y Reis; Ran D Balicer; Noa Dagan
Journal:  N Engl J Med       Date:  2022-04-13       Impact factor: 176.079

9.  COVID-19 Mortality and Vaccine Coverage - Hong Kong Special Administrative Region, China, January 6, 2022-March 21, 2022.

Authors:  Dallas J Smith; Avi J Hakim; Gabriel M Leung; Wenbo Xu; W William Schluter; Ryan T Novak; Barbara Marston; Bradley S Hersh
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2022-04-15       Impact factor: 35.301

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.